Pharmaceutical teams should move from checkbox penetration tests to continuous, risk-based testing that focuses on critical assets, likely attacker paths, and root causes of weakness. That means prioritising intellectual property, clinical data, exposed applications, and supply chain entry points, then validating whether controls actually reduce exploitable risk rather than simply satisfying audit requirements. The goal is to stay ahead of adversaries, not just prove compliance.
What Risk-Based Testing Changes in Practice
Risk-based testing changes the unit of work from “prove the control exists” to “prove the control reduces meaningful exposure.” For pharmaceutical environments, that means testing is driven by the value of the asset, the plausibility of the attack path, and the harm that follows compromise. A test plan should therefore distinguish research data, manufacturing-adjacent systems, partner connections, and externally reachable services rather than treating every control as equally important.
The practical shift is from periodic assurance to continuous prioritisation. Teams should expect testing scope to move as the threat surface changes, especially where exposed applications, third-party dependencies, or high-value data stores create a larger blast radius. In that model, a finding is important not because it failed a checklist item, but because it shows an attacker could reach a critical asset, persist, or exfiltrate something the business cannot easily replace.
- Focus test design on likely attacker paths, not on evenly sampling every system.
- Re-test controls when business criticality, exposure, or dependency chains change.
- Treat repeated findings on crown-jewel systems as a signal of weak control design, not just local misconfiguration.
Where Pharmaceutical Risk Concentrates
The most useful testing targets in pharma are usually the places where sensitive research, regulated data, or external trust relationships intersect. Intellectual property, clinical data, manufacturing support systems, and supplier or partner access often deserve different test depth because the impact of compromise is not equal. A low-value internal application may justify a lighter validation effort, while a path into a laboratory, trial repository, or connected production-support environment warrants deeper adversarial testing.
Risk-based testing also needs to account for how weak points combine. A single exposed application may be tolerable in isolation, but if it provides a route into credential stores, shared services, or vendor connectivity, the security question becomes chainability. That is why root-cause analysis matters: if repeated findings come from poor segmentation, weak authentication boundaries, or unmanaged external access, the real issue is not the individual defect but the pattern that keeps recreating exposure.
For teams trying to anchor their approach in broader control thinking, ISO/IEC 27001:2022 Information Security Management supports a risk-led view of security governance, while ISO/IEC 27002:2022 Information Security Controls helps translate that into practical control selection and validation.
How to Operationalise the Shift
The operational mistake to avoid is replacing one calendar-driven test with another. Risk-based testing works when it is tied to an asset inventory, data classification, exposure mapping, and a clear rule for what qualifies as critical. The testing programme should then use those inputs to set depth, frequency, and retesting priority. High-risk systems should be validated more often and more adversarially, while lower-risk assets may only need lighter verification unless something changes.
Good programmes also validate outcomes, not just outputs. If a test uncovers a weakness, the follow-up question is whether the remediation actually reduced exploitability, shortened access, or blocked the attacker path. Teams should be able to show which risks were accepted, which were reduced, and which remain open because the control is ineffective, incomplete, or too dependent on manual process.
If the programme needs a more structured testing method for web and API-facing systems, OWASP Web Security Testing Guide provides a practical testing baseline, and NIST Cybersecurity Framework 2.0 is useful for organising governance, identification, protection, detection, response, and recovery around the same risk priorities.
Risk and Threat Considerations
When pharmaceutical testing stays compliance-led, the main danger is false confidence. A control can pass audit and still leave an attacker with a workable route into valuable research, clinical, or partner-connected assets. The highest risk usually appears where exposure, privilege, and third-party access meet, because those conditions make compromise more scalable and harder to contain.
Failure mechanism: Teams test what is easy to verify instead of what is most exploitable, so recurring weaknesses in externally reachable systems, supplier connections, or high-value repositories remain under-tested.
Impact: Attackers can pivot from a modest finding to data theft, disruption, or broader trust compromise, while the organisation wrongly assumes its control set is adequate because the checklist was complete.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
OWASP Non-Human Identity Top 10 address the attack surface, NIST CSF 2.0 and CIS Controls v8 set the technical controls, and ISO/IEC 42001:2023 define the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| ISO/IEC 42001:2023 | 4.1 — Understanding the organization and its context | Pharma risk-based testing must reflect business-critical assets and exposure context. |
| Recommendation — Align test scope to the organisation’s critical assets, exposures, and business context. | ||
| NIST CSF 2.0 | ID.AM-1 — Physical devices and systems inventoried | Risk-based testing depends on knowing which assets exist and which are critical. |
| ID.RA-1 — Asset vulnerabilities identified and documented | The shift from compliance checks to risk-based testing requires vulnerability discovery tied to impact. | |
| PR.DS-4 — Information is managed consistent with risk strategy | Pharma testing must validate whether protections reduce risk to sensitive research and clinical data. | |
| Recommendation — Maintain an accurate asset inventory to drive testing priority and coverage. Identify and document vulnerabilities against the assets that matter most. Validate controls that protect sensitive data against the organisation’s risk strategy. | ||
| CIS Controls v8 | 18 — Penetration Testing | This question is directly about moving from checkbox tests to more realistic penetration testing. |
| Recommendation — Use penetration testing to validate exploitable paths against critical assets and likely attack routes. | ||
| OWASP Non-Human Identity Top 10 | NHI-01 — Secrets and Credential Management | Pharma testing often exposes credential and secret weaknesses that create real attack paths. |
| NHI-05 — Overprivileged Non-Human Identities | Excess privilege is a common root cause of exploitable paths in connected environments. | |
| Recommendation — Test whether secrets handling and credential controls actually prevent abuse of access paths. Check whether overprivileged identities expand reach into critical systems. | ||
Practitioner Guidance
What to prioritise: Build the testing queue from asset criticality and attack path plausibility, then use change events, not the audit calendar, to decide when re-testing is mandatory. In pharma, the fastest path to better coverage is usually to separate crown-jewel systems from ordinary enterprise assets and test them with different depth and cadence.
What to verify: For each high-risk finding, verify whether the remediation changes the attacker path, reduces privilege, or blocks reachability. If a fix only satisfies a control narrative but does not alter exploitability, treat it as incomplete.
Practitioner takeaway: Risk-based testing only works when the team measures whether a weakness can actually be used against a critical asset, not whether a control can be checked off.
Related resources from NHI Mgmt Group
- Why does vulnerability testing matter when security teams are trying to reduce breach risk and support compliance?
- How should security teams implement CTEM as a risk-based programme instead of a compliance exercise?
- How should security teams shift from manual security reviews to a risk-based secure development lifecycle?
- How should security teams use PAM to improve both compliance and risk reduction?
Deepen Your Knowledge
Reviewed and updated by the NHIMG editorial team on September 18, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org
